These are Lung Cancer TMAs sourced from LCBRN cases.  Both TMAs are well-annotated with clinicopathology data and represent a limited number of cases that may detect strong trends in differential gene expression and is intended for pilot surveys and generation of hypotheses. They do not contain case numbers of sufficient quantity to prove the clinical utility of a marker.